Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.

TitleSerotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer's Disease Patients with Depressive Symptoms.
Publication TypeJournal Article
Year of Publication2018
AuthorsBrendel, M, Sauerbeck, J, Greven, S, Kotz, S, Scheiwein, F, Blautzik, J, Delker, A, Pogarell, O, Ishii, K, Bartenstein, P, Rominger, A
Corporate AuthorsAlzheimer’s Disease Neuroimaging Initiative
JournalJ Alzheimers Dis
Volume65
Issue3
Pagination793-806
Date Published2018
ISSN1875-8908
Abstract

Late-life depression, even when of subsyndromal severity, has shown strong associations with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Preclinical studies have suggested that serotonin selective reuptake inhibitors (SSRIs) can attenuate amyloidogenesis. Therefore, we aimed to investigate the effect of SSRI medication on amyloidosis and grey matter volume in subsyndromal depressed subjects with MCI and AD during an interval of two years. 256 cognitively affected subjects (225 MCI/ 31 AD) undergoing [18F]-AV45-PET and MRI at baseline and 2-year follow-up were selected from the ADNI database. Subjects with a positive depression item (DEP(+); n = 73) in the Neuropsychiatric Inventory Questionnaire were subdivided to those receiving SSRI medication (SSRI(+); n = 24) and those without SSRI treatment (SSRI(-); n = 49). Longitudinal cognition (Δ-ADAS), amyloid deposition rate (standardized uptake value, using white matter as reference region (SUVRWM), and changes in grey matter volume were compared using common covariates. Analyses were performed separately in all subjects and in the subgroup of amyloid-positive subjects. Cognitive performance in DEP(+)/SSRI(+) subjects (Δ-ADAS: -5.0%) showed less deterioration with 2-year follow-up when compared to DEP(+)/SSRI(-) subjects (Δ-ADAS: +18.6%, p

DOI10.3233/JAD-170387
Alternate JournalJ. Alzheimers Dis.
PubMed ID30010116
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

Source URL: https://www.j-alz.com/content/serotonin-selective-reuptake-inhibitor-treatment-improves-cognition-and-grey-matter-atrophy